Chen, L
Zhao, Y
Halliday, G C
Berry, P
Rousseau, R F
Middleton, S A
Nichols, G L
Del Bello, F
Piergentili, A
Newell, D R
Lunec, J
Tweddle, D A
Article History
Received: 21 February 2014
Revised: 9 May 2014
Accepted: 13 May 2014
First Online: 12 June 2014
Competing interests
: L Chen and DA Tweddle are part of an international collaborative research consortium with Hoffmann-La Roche Inc. DR Newell is co-director of the CRUK funded Drug Discovery Programme at Newcastle University which developed NDD0005 and in which J Lunec and DA Tweddle are collaborative co-investigators. Newcastle University, Cancer Research Technology and Astex Pharmaceuticals Inc. are part of an alliance agreement since 2012 and DR Newell has received research funding from Astex Pharmaceuticals, Inc. RF Rousseau is employed by Genentech Inc., and SA Middleton and GL Nichols are employed by Hoffmann-La Roche. The remaining authors declare no conflict of interest.